Sanofi US News

Companies also announce submission of dupilumab supplemental BLA for uncontrolled, persistent asthma

High and durable response rate in disease without any FDA-approved therapies

* First FDA-approved follow-on mealtime insulin

Phase 3 trials will evaluate isatuximab, an anti-CD38 antibody, in combination with other cancer treatments 

First head-to-head randomized clinical trial comparing the efficacy and safety of Toujeo (insulin glargine 300 Units/mL) versus insulin degludec

Two large real-world analyses compared adults with type 2 diabetes who were switched to Toujeo (insulin glargine injection 300 Units/mL) to those switched to insulin degludec

- Understand AD: A Day in the Life, Raises Awareness of Atopic Dermatitis by Sharing Real Stories from the AD Community, Driving Empathy and Understanding of this Unrelenting, Chronic Disease -

- In preclinical studies, trispecific antibodies show exceptional potency against diverse HIV viruses -

- Investigational RNAi Therapeutic Patisiran Meets Primary and All Secondary Endpoints, with Highly Significant Reduction In Neuropathy Progression and Improvement in Quality of Life at 18 Months Relative to Placebo -

-- More adults reached HbA(1c) target at 8 and 12 weeks versus those receiving insulin glargine 100 Units/mL --

- Investigational dupilumab reduced severe asthma attacks and improved lung function -

- Data presented at the 77th Scientific Sessions of the American Diabetes Association (ADA) -

- All subgroups treated with Soliqua 100/33 achieved a mean HbA1c of below 7 percent after 30 weeks -

- New DELIVER 3 Real-World Toujeo® Observational Study Confirms Reduction of Hypoglycemia in Real-Life Setting -

- Oral presentation provides first REGN2810 data in patients with advanced cutaneous squamous cell carcinoma (CSCC) -

- Kevzara is now available to U.S. patients -

-- New Initiative Encourages Americans to Help Reduce Air Pollution & Enjoy the Outdoors this Spring Allergy Season --

Op-Ed by Olivier Brandicourt

- New U.S. survey reveals significant unmet needs when it comes to treatments and support for those living with RA -

- New action date for Kevzara U.S. BLA is May 22, 2017 -

- Monthly dosing schedule now approved in both United States and European Union -

- New U.S. indication approved for Thymoglobulin [anti-thymocyte globulin (rabbit)]; first since 1998 -

- DELIVER 2 Data Showed Reduction in Hypoglycemic Events Related to Inpatient or Emergency Department Visits -

- Dupixent will be available later this week to U.S. patients suffering from this chronic and debilitating form of eczema -

- During Multiple Myeloma Month Sanofi Genzyme is Reinforcing its Commitment to Help Patients Live with the Second Most Common Blood Cancer in the World -

The makers of Xyzal® Allergy 24HR, now available over-the-counter (OTC) at full prescription strength, are teaming up with Dr. Neeta Ogden to Encourage Allergy Sufferers to 'Wise Up, Rise Up'

- Late-breaking oral abstract to be presented today at the Annual Meeting of the American Academy of Dermatology -

- Praluent continues to be available to patients in the U.S. -

- Antihistamine Offers 24-Hour Relief to Adults and Children with Seasonal and Year-Round Allergies -

Data also Shows Men Consider Sexual Health to be an Important Priority

- In the MONARCH Study, Sarilumab Monotherapy Demonstrated Superiority Over Adalimumab Monotherapy in Adults with Active Rheumatoid Arthritis -

- U.S. adults report issues with sleep, ability to work and feelings of depression and anxiety -

- Data to be presented today during a late breaking abstract session at the 25th Annual European Academy of Dermatology and Venereology (EADV) Congress -

- Joshua Riff, M.D., Named Chief Executive Officer -

- Adlyxin™ is approved as Lyxumia® in more than 60 countries -

Falkner has joined forces with Regeneron and Sanofi Genzyme in collaboration with leading dermatology organizations to educate Americans about a potentially serious, chronic inflammatory skin disease known as atopic dermatitis.

- Both pivotal studies demonstrated superior reduction in HbA1c versus insulin glargine and versus lixisenatide -

- These data, along with previous Phase 3 studies, will be part of a U.S. regulatory submission for dupilumab, which is on track for Q3 of 2016 -

- FDA decisions on the investigational fixed-ratio combination of basal insulin glargine 100 Units/mL and GLP-1 receptor agonist lixisenatide and investigational lixisenatide anticipated in Q3 2016 -

- Collaborations Will Work towards Predicting Medication Adherence -

- FDA decision anticipated in August 2016 -

America's Leading National Consumer Research Survey Ranks ACT Advanced Care #1 in "Oral Care" Category

Study Evaluated Adult Patients with Chronic Sinusitis with Nasal Polyposis who did not Respond to Intranasal Corticosteroids

Six researchers each receive $1.625 million in "Pathway to Stop Diabetes®" awards

New 24 and 32-Packs Designed to Manage Dosage Regimens for both Latent and Active Tuberculosis

- A study conducted with 1,500 Americans in July 2015 examined perceived risks of counterfeit medicines[1] -

- First New Drug Application for a GLP-1 receptor agonist to include CV outcomes data -

- LixiLan met primary endpoint showing superior reduction in HbA1c vs Insulin Glargine alone -

- Will work together on new digital technology and tools for diabetes -

- Praluent available early next week to U.S. patients -

- ELIXA is the first event-driven cardiovascular outcomes study to provide data for a GLP-1 receptor agonist -

- Includes study in patients who were inadequate responders to, or intolerant of, TNF-alpha inhibitors -

- Results support resubmission of U.S. New Drug Application in Q3 2015 -

Further education about hypoglycemia and routinely monitoring blood glucose levels is needed

- Primary efficacy endpoints met in two trials of alirocumab administered every four weeks -

Awards will provide funding for innovative diabetes researchers